Dayoub, H; Achan, V; Adimoolam, S; Jacobi, J; Stuehlinger, MC; Wang, BY; ... Cooke, JP; + view all Dayoub, H; Achan, V; Adimoolam, S; Jacobi, J; Stuehlinger, MC; Wang, BY; Tsao, PS; Kimoto, M; Vallance, P; Patterson, AJ; Cooke, JP; - view fewer (2003) Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation , 108 (24) 3042 - 3047.
Full text not available from this repository.
BACKGROUND: NO is a major regulator of cardiovascular physiology that reduces vascular and cardiac contractility. Accumulating evidence indicates that endogenous inhibitors may regulate NOS. The NOS inhibitors asymmetric dimethylarginine (ADMA) and N-monomethylarginine are metabolized by the enzyme dimethylarginine dimethylaminohydrolase (DDAH). This study was designed to determine if increased expression of DDAH could reduce tissue and plasma levels of the NOS inhibitors and thereby increase NO synthesis. METHODS AND RESULTS: We used gene transfer and transgenic approaches to overexpress human DDAH I in vitro and in vivo. The overexpression of DDAH in cultured endothelial cells in vitro induced a 2-fold increase in NOS activity and NO production. In the hDDAH-1 transgenic mice, we observed approximately 2-fold increases in tissue NOS activity and urinary nitrogen oxides, associated with a 2-fold reduction in plasma ADMA. The systolic blood pressure of transgenic mice was 13 mm Hg lower than that of wild-type controls (P<0.05). The systemic vascular resistance and cardiac contractility were decreased in response to the increase in NO production. CONCLUSIONS: DDAH I overexpression increases NOS activity in vitro and in vivo. The hDDAH-1 transgenic animal exhibits a reduced systolic blood pressure, systemic vascular resistance, and cardiac stroke volume. This study provides compelling evidence that the elaboration and metabolism of endogenous ADMA plays an important role in regulation of NOS activity
|Title:||Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence|
|Additional information:||DA - 20031216 IS - 1524-4539 LA - eng PT - Journal Article RN - 10102-43-9 (Nitric Oxide) RN - 30315-93-6 (N,N-dimethylarginine) RN - 74-79-3 (Arginine) RN - EC 184.108.40.206 (Nitric-Oxide Synthase) RN - EC 3.5. (Amidohydrolases) RN - EC 220.127.116.11 (dimethylargininase) SB - AIM SB - IM|
|Keywords:||activity, Amidohydrolases, analogs & derivatives, Animal, Animals, Arginine, biosynthesis, Blood, Blood Pressure, BLOOD-PRESSURE, cardiac, cardiovascular, Cardiovascular Physiology, cell, CELLS, Cells, Cultured, contractility, control, endogenous, Endothelial, endothelial cell, endothelial cells, ENDOTHELIAL-CELLS, Endothelium, enzyme, expression, GENE, Gene transfer, genetic, genetics, Hemodynamic Processes, IM, in vitro, in vivo, In-vitro, in-vivo, INCREASE, INCREASES, INDICATE, INHIBITOR, INHIBITORS, LA, LEVEL, May, metabolism, Methods, mice, Mice, Inbred C57BL, Mice, Transgenic, MM, nitric oxide, nitric oxide synthase, NITRIC-OXIDE, Nitric-Oxide Synthase, Nitrogen, NOS, OVEREXPRESSION, OXIDE, oxides, PHYSIOLOGICAL, physiology, plasma, play, Pressure, REDUCTION, regulation, Resistance, response, Result, stroke, Stroke Volume, Support, Non-U.S.Gov't, Support, U.S.Gov't, P.H.S., SYNTHASE, synthesis, SYSTEMIC, Tissue, Transfection, transgenic, transgenic mice, URINARY, vascular, Vascular Resistance, VITRO, vivo, volume|
|UCL classification:||UCL > School of Life and Medical Sciences > Faculty of Medical Sciences > Medicine (Division of)|
Archive Staff Only: edit this record